Share this article
Share this article
LEXINGTON, Mass., March 16, 2021 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2020. 2020 was a transformative year for Curis, as we made significant progress in our mission to develop the next generation of targeted cancer therapies that meaningfully improve and extend the lives of patients. Despite the difficulties and uncertainty brought about by the ongoing coronavirus pandemic, we significantly advanced and expanded each program in our clinical pipeline, headlined by the very encouraging data from our Phase 1 trials of lead asset, CA-4948, presented in December in conjunction with ASH, said James Dentzer, President and Chief Executive Officer of Curis. We look forward to providing additional updates on our IRAK4 program throughout the year, with
Anthony J. Cataldo, GT Biopharma s Chairman and Chief Executive Officer, commented: It is exciting to announce the addition of a second clinical trial site for our Phase I/II program of our novel GTB-3550 TriKE™ program. With this progress, we are closer to bringing our disruptive and target-directed NK cell engager approach to patients in need. We are grateful to the valiant patients and their families, as we continue to progress this initial indication trial of our first-in-class NK cell protein biologic cancer therapy.
GTB-3550 TriKE™ is being evaluated in patients age 18 and older with CD33+ malignancies (primary induction failure or relapsed acute myeloid leukemia [AML] with failure of one reinduction attempt, or high-risk myelodysplastic syndromes [MDS] progressed on two lines of therapy). The primary endpoint is to identify the maximum tolerated dose and safety of GTB-3550 TriKE™ therapy. Correlative objectives include the number, phenotype, activation status and func
At 3 a.m., Imeria Price and Jordan Washington got
up to take their 8-year-old son to the emergency room. Jakobe had fallen ill earlier that day at a baseball tournament in Georgia, so they returned home to Punta Gorda.
At first, his symptoms resembled a typical infection. Sore throat. Swollen lymph nodes. Fatigue. Then came the blood-red spots on his mouth.
From
the hospital, a helicopter
flew Jakobe to Johns Hopkins All Childrenâs Hospital in St. Petersburg, a 25-minute ride. His parents trailed behind, a 2-hour car journey ahead of them, unsure what would come next.
A doctor called them about
Sierra Oncology Reports 2020 Year End Results
News provided by
Share this article
Share this article
– MOMENTUM Phase 3 Trial on Track to Complete Enrollment in mid-2021 with Top-line Data Anticipated in H1 2022 –
– Data Presented Throughout the Year Included Long-Term Overall Survival, Efficacy in Various
Patient Subsets and Dosing Durability –
– Key Appointments Made to Executive Team in Preparation for Commercial Execution –
SAN MATEO, Calif., March 11, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operational results for the fourth quarter and fiscal year ended December 31, 2020.